IN2014DN08830A - - Google Patents

Download PDF

Info

Publication number
IN2014DN08830A
IN2014DN08830A IN8830DEN2014A IN2014DN08830A IN 2014DN08830 A IN2014DN08830 A IN 2014DN08830A IN 8830DEN2014 A IN8830DEN2014 A IN 8830DEN2014A IN 2014DN08830 A IN2014DN08830 A IN 2014DN08830A
Authority
IN
India
Prior art keywords
eliciting
immune response
compositions
useful
individual
Prior art date
Application number
Other languages
English (en)
Inventor
Richard C Duke
Alex Franzusoff
Aurelia Haller
Thomas H King
Yingnian Lu
Victoria Kelley Hodson
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of IN2014DN08830A publication Critical patent/IN2014DN08830A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IN8830DEN2014 2006-02-02 2007-02-02 IN2014DN08830A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
PCT/US2007/061572 WO2007092792A2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Publications (1)

Publication Number Publication Date
IN2014DN08830A true IN2014DN08830A (cg-RX-API-DMAC7.html) 2015-07-10

Family

ID=38345897

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8830DEN2014 IN2014DN08830A (cg-RX-API-DMAC7.html) 2006-02-02 2007-02-02

Country Status (14)

Country Link
US (2) US7736642B2 (cg-RX-API-DMAC7.html)
EP (2) EP1988919A4 (cg-RX-API-DMAC7.html)
JP (3) JP5198290B2 (cg-RX-API-DMAC7.html)
KR (2) KR20140029551A (cg-RX-API-DMAC7.html)
CN (2) CN104826102A (cg-RX-API-DMAC7.html)
AU (1) AU2007212076B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0706913A2 (cg-RX-API-DMAC7.html)
CA (1) CA2638815A1 (cg-RX-API-DMAC7.html)
IL (2) IL193196A (cg-RX-API-DMAC7.html)
IN (1) IN2014DN08830A (cg-RX-API-DMAC7.html)
MX (1) MX2008009929A (cg-RX-API-DMAC7.html)
SG (2) SG10201402236VA (cg-RX-API-DMAC7.html)
TW (2) TW200806316A (cg-RX-API-DMAC7.html)
WO (1) WO2007092792A2 (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
WO2004058157A2 (en) * 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US20100034840A1 (en) * 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
EP1988919A4 (en) * 2006-02-02 2009-06-10 Globeimmune Inc VAKZINE ON YEAST BASE FOR TRIGGERING AN IMMUNE RESPONSE
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
US20100143393A1 (en) * 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
DK2023952T3 (en) * 2006-05-18 2015-10-19 Epimmune Inc Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2121013B1 (en) * 2007-02-02 2014-10-15 Globeimmune, Inc. Methods for producing yeast-based vaccines
US8501167B2 (en) * 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
EP2419126B1 (en) 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
JP2012527232A (ja) * 2009-05-18 2012-11-08 パナセア バイオテック リミテッド 遺伝子組換え改変ワクシニアアンカラウイルス（ｍｖａ）ベースのインフルエンザ万能ワクチン
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
WO2012006561A2 (en) * 2010-07-08 2012-01-12 New York Medical College Influenza virus detection and diagnosis
SG189236A1 (en) * 2010-10-04 2013-05-31 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
AU2011316164B2 (en) * 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
WO2012083302A2 (en) 2010-12-17 2012-06-21 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
US9463237B2 (en) * 2011-01-31 2016-10-11 Baxalta Incorporated Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses
CN103476426B (zh) 2011-02-12 2021-08-10 全球免疫股份有限公司 用于慢性乙型肝炎病毒感染的基于酵母的治疗剂
RU2690180C2 (ru) * 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
US20140377295A1 (en) * 2011-05-23 2014-12-25 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
SG10201605265TA (en) 2011-06-14 2016-08-30 Globeimmune Inc Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection
CN103732749B (zh) * 2011-06-20 2017-03-29 高等教育联邦系统-匹兹堡大学 计算优化的宽反应性的h1n1流感抗原
BR112014003477B1 (pt) 2011-08-17 2021-11-03 Globeimmune, Inc. Composição imunoterapêutica de muc1 de levedura
PL2591798T3 (pl) 2011-11-09 2015-04-30 Werner Lubitz Szczepionka do zastosowania w immunoterapii nowotworów
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
AU2013281221B2 (en) 2012-06-26 2018-05-17 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
AU2013359469B2 (en) * 2012-12-10 2019-05-16 Seattle Biomedical Research Institute Cell-free biofragment compositions and related systems, devices, and methods
WO2014151279A1 (en) * 2013-03-15 2014-09-25 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-23 as an adjuvant
WO2014186047A1 (en) 2013-03-19 2014-11-20 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
TWI728239B (zh) * 2013-03-26 2021-05-21 美商環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
EP4070818A3 (en) 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
EP3113759B1 (en) 2014-03-05 2021-05-12 Orbis Health Solutions LLC Vaccine delivery systems using yeast cell wall particles
WO2015157639A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
WO2016168187A1 (en) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Virus-like particles
JP6789283B2 (ja) 2015-08-03 2020-11-25 グローブイミューン，インコーポレイテッド 改変酵母−ブラキュリー免疫療法組成物
JP6956067B2 (ja) * 2015-08-11 2021-10-27 オービス ヘルス ソリューションズ エルエルシー 細菌およびウイルスのワクチン戦略
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
US11154597B2 (en) 2016-03-24 2021-10-26 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
SG11201909882SA (en) 2017-04-24 2019-11-28 Nantcell Inc Targeted neoepitope vectors and methods therefor
WO2019124557A1 (ja) 2017-12-21 2019-06-27 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
WO2019222073A1 (en) 2018-05-15 2019-11-21 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
EP3851120A4 (en) * 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
CN114269374A (zh) * 2019-05-21 2022-04-01 艾斯佩罗疫苗公司 基于酵母的口服疫苗接种
JP2023515355A (ja) * 2020-02-11 2023-04-13 サイトナス セラピューティクス，インク． 高速ワクチンプラットフォーム
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
CA3170359A1 (en) 2020-04-14 2021-10-21 Nantcell, Inc. Yeast lysate covid-19 vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
CN1149888A (zh) * 1994-01-11 1997-05-14 福拉姆斯大学生物技术研究所 流感疫苗
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
KR100877019B1 (ko) * 2000-06-23 2009-01-07 와이어쓰 홀딩스 코포레이션 야생형 및 키메릭 인플루엔자 바이러스성입자(브이엘피)의 조립
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
WO2004058157A2 (en) * 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CA2566355C (en) * 2004-05-18 2014-04-15 Vical Incorporated Influenza virus vaccine composition and methods of use
ATE536175T1 (de) * 2004-09-17 2011-12-15 Univ Massachusetts Zusammensetzungen und ihre verwendungen bei lysosomalen enzymstörungen
EP1988919A4 (en) * 2006-02-02 2009-06-10 Globeimmune Inc VAKZINE ON YEAST BASE FOR TRIGGERING AN IMMUNE RESPONSE

Also Published As

Publication number Publication date
KR20080089671A (ko) 2008-10-07
JP2013075899A (ja) 2013-04-25
EP2468296A3 (en) 2013-12-04
US20080003239A1 (en) 2008-01-03
CN101405026A (zh) 2009-04-08
JP2015038147A (ja) 2015-02-26
IL232518A0 (en) 2014-06-30
JP2009528987A (ja) 2009-08-13
US7736642B2 (en) 2010-06-15
KR20140029551A (ko) 2014-03-10
IL193196A0 (en) 2011-08-01
TW201412329A (zh) 2014-04-01
WO2007092792A2 (en) 2007-08-16
IL193196A (en) 2015-01-29
EP1988919A2 (en) 2008-11-12
MX2008009929A (es) 2008-10-01
CA2638815A1 (en) 2007-08-16
CN101405026B (zh) 2015-04-22
AU2007212076A1 (en) 2007-08-16
JP5198290B2 (ja) 2013-05-15
KR101492524B1 (ko) 2015-02-12
EP2468296A2 (en) 2012-06-27
TW200806316A (en) 2008-02-01
SG10201402236VA (en) 2014-08-28
EP1988919A4 (en) 2009-06-10
SG169375A1 (en) 2011-03-30
WO2007092792A3 (en) 2008-02-28
AU2007212076B2 (en) 2012-10-18
US20100196411A1 (en) 2010-08-05
CN104826102A (zh) 2015-08-12
BRPI0706913A2 (pt) 2011-04-12

Similar Documents

Publication Publication Date Title
IN2014DN08830A (cg-RX-API-DMAC7.html)
WO2010019262A3 (en) Polyvalent vaccine
WO2007024941A3 (en) Polyvalent vaccine
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2009156960A3 (en) Novel adjuvant compositions
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
WO2010060051A3 (en) Systems biology approach predicts the immunogenicity of vaccines
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
MX2009006178A (es) Vacuna contra salmonela.
CA2763359C (en) New human rotavirus strains and vaccines
IN2014DN09791A (cg-RX-API-DMAC7.html)
WO2009135199A3 (en) Vaccine compositions and methods
HK1211980A1 (en) Multifunctional oral vaccine based on chromosome recombineering
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
WO2011074006A3 (en) Vaccine composition
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
WO2007120860A3 (en) Nanoemulsion vaccines
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing